THE FUTURE OF NON-ADDICTIVE PAIN MANAGEMENT
Mark Identification

THE FUTURE OF NON-ADDICTIVE PAIN MANAGEMENT

Serial Number

88165746

Filing Date

Oct 23, 2018

Registration Date

Jun 13, 2023

Trademark by

VIVERA PHARMACEUTICALS INC.

Active Trademark

Classification Information

Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of orodispersable tablets and/or sublingual tablets that facilitate the delivery of pharmaceutical preparations; Pain relief medication; Pharmaceutical preparations for the treatment and prevention of chronic pain; Pharmaceutical preparations for the treatment of the cardiovascular system, the circulatory system, the digestive system, the excretory system, the endocrine system, the integumentary system, the exocrine system, the lymphatic system, the immune system, the muscular system, the nervous system, the renal system, the urinary system, the reproductive system, and/or the skeletal system; Pharmaceutical preparations for non-addictive pain management; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Chemical preparations for pharmaceutical or medical purposes, namely, for non-addictive pain management; none of the foregoing items comprised of Cannabis sativa L with a delta-9 tetrahydrocannabinol (THC) content of more than 0.3 percent on a dry weight basis and none of which are comprised of cannabidiol (CBD)

Pharmaceuticals